SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

mRNA-2808

MRNA·Moderna, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2
Time to market
Several years away, if ever. The drug is in Phase 1/2 dose-escalation; a registrational path has not been defined.
Why 4/10
The next hard, dated catalyst is the oral presentation of initial Phase 1/2 data at the 68th ASH Annual Meeting in December 2026. That data has already been previewed (4 confirmed responses in 11 patients), so the ASH presentation is a full-data readout of already-telegraphed early results, not a binary approval or pivotal readout.
Actionable Insight NEUTRAL

Watch for the full ASH 2026 oral presentation in December 2026 for deeper efficacy and safety details (duration of response, cytokine release syndrome rates). The early 36% response rate in heavily pretreated patients is encouraging but very early. Moderna has a second T-cell engager (mRNA-2151) in ovarian cancer that could validate the platform if mRNA-2808 data holds up.

Price Chart

Loading chart...

Executive Summary

mRNA-2808 is Moderna's first clinical-stage mRNA-based T-cell engager, targeting relapsed or refractory multiple myeloma. It is an early-stage (Phase 1/2) asset that uses Moderna's mRNA platform to make the body produce three anti-cancer proteins simultaneously. On November 4, 2026, Moderna announced initial data showing 4 confirmed responses among 11 heavily pretreated patients, and the data was accepted for oral presentation at the ASH 2026 annual meeting in December. While the early efficacy signal is encouraging for a proof-of-concept, the drug is years from any regulatory decision, and multiple myeloma is a competitive landscape with approved bispecific antibodies and CAR-T therapies. mRNA-2808 represents a small part of Moderna's broad pipeline; the company's valuation is driven primarily by its COVID-19 vaccine franchise and its personalized cancer vaccine (intismeran) partnership with Merck.

How It Works

mRNA-2808 is an mRNA-based T-cell engager (TCE). It works by delivering genetic instructions (mRNA) into the patient's body that instruct their own cells to produce three cancer-fighting proteins at once. These proteins help redirect the patient's immune T-cells to recognize and kill multiple myeloma cancer cells. It is a "multiplexed" approach, meaning a single mRNA drug encodes multiple therapeutic proteins.

Trial Status

First patient dosed in November 2025. Initial data from 11 heavily pretreated relapsed/refractory multiple myeloma patients showed 4 confirmed responses (36% response rate). The data was selected for oral presentation at the 68th ASH Annual Meeting in December 2026. The trial is ongoing and enrolling.

The Two-Sided Case

▲ Bull Case4
Early data showed 4 confirmed responses among 11 heavily pretreated multiple myeloma patients (36% response rate), a meaningful signal in a difficult-to-treat population.
The multiplexed mRNA approach (encoding three anti-cancer proteins from a single drug) is novel and could offer advantages over traditional biologics manufacturing.
Moderna's Science Day in June 2026 highlighted mRNA-2808 as validation of the T-cell engager modality, supporting a second TCE (mRNA-2151) in ovarian cancer.
Moderna has deep pockets and commercial infrastructure from its COVID franchise, so the drug has strong development resources behind it.
▼ Bear Case5
The drug is in very early Phase 1/2 dose-escalation with only 11 patients reported; response rates often change as larger cohorts are enrolled.
Multiple myeloma is a crowded field with approved bispecific antibodies (e.g., teclistamab, elranatamab), CAR-T therapies (e.g., Carvykti, Abecma), and many other T-cell engagers in development from J&J, AbbVie, GSK, and others.
mRNA-2808 is a small part of Moderna's pipeline; the stock's 545%+ YTD rally in 2026 was driven primarily by the intismeran (personalized cancer vaccine) data and COVID vaccine sales, not this asset.
The ASCO 2026 abstract (TPS7580) was a trial-in-progress poster, indicating the study was still in early enrollment as of mid-2026.
Moderna President Stephen Hoge sold shares worth roughly $17M in October 2026 under a 10b5-1 plan, though these were pre-planned sales.

Upcoming Catalysts

  • Oral presentation of full Phase 1/2 data at the 68th ASH Annual Meeting in December 2026.
  • Dose-escalation updates and potential expansion cohort data as the Phase 1/2 study continues to enroll.
  • Potential initiation of a Phase 2 expansion cohort or combination study if safety and efficacy data remain favorable.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Moderna, Inc. 8-K MRNA ·Originating report

Sources · 6

Hover a chip for the title
1 newswire.com2 newswire.com3 ascopubs.org4 biospace.com5 usatoday.com6 msn.com